Primary platelet activation in recent-onset type 1 diabetes mellitus

Vicari, A.; Macagni, A

doi:10.3109/00365519009091602

Cited by 17 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the finding of signs of platelet activation in animal models (33) and in young patients with uncomplicated IDDM of very recent onset (34) suggests an alternative, non-complication-dependent pathogenesis. The results of this study indicate that an unsatisfying metabolic control determines an increase of [Ca 2+ ]i in the platelets of IDDM patients.…”

Section: Conclusion-mentioning

confidence: 91%

Deranged Platelet Calcium Homeostasis in Poorly Controlled IDDM Patients

et al. 1993

View full text Add to dashboard Cite

show abstract

Section: Conclusion-mentioning

confidence: 91%

Deranged Platelet Calcium Homeostasis in Poorly Controlled IDDM Patients

et al. 1993

View full text Add to dashboard Cite

show abstract

“…Platelet activation, the process of increased cell surface expression of binding receptors and release of vasoactive substances, has been shown at an early stage in diabetes and in insulin resistant states, [8][9][10] in the absence of overt cardiovascular disease, suggesting that this altered platelet activity may contribute to the subsequent development of vasculopathy. 11 Diabetes, insulin resistance and hyperglycaemia are all pro-coagulant states, [12][13][14][15] enhancing clot stability, increasing its propagation and inhibiting thrombus dissolution. 16 Enhanced expression of plasminogen activator inhibitor-1 (PAI-1) has been demonstrated in insulin resistance, 17 and down regulation of antithrombin III (ATIII) activity, by non-enzymatic glycosylation, has been shown to reduce its in vitro thrombin inhibiting activity.…”

Section: Mechanisms Of Increased Risk In Diabetes? (Figure 2) Platelementioning

confidence: 99%

Review: The management of stable angina in diabetes

Williams¹,

Vazir²,

Zaman

2003

Diabetes & Vascular Disease

View full text Add to dashboard Cite

Cardiovascular atherosclerosis is the commonest underlying cause of death in patients with diabetes mellitus. The development of atherosclerosis is often accelerated and the outcome is worse in diabetic than non-diabetic patients. This may relate to abnormalities of platelet function, coagulation, blood pressure and lipid metabolism that are characteristic of diabetes. Management of angina in diabetes should focus on reducing symptoms and prolonging life. In both of these areas there are issues specific to the diabetic patient. The role of percutaneous and surgical approaches to coronary disease in diabetic patients continues to evolve and optimal therapy remains unclear. Herein explores the clinical management of coronary artery disease in patients with diabetes. The pathophysiological basis of stable and unstable coronary syndromes is explained and the effect of diabetes on coronary disease and its subsequent management is discussed.

show abstract

“…Increased MPV may be the consequence of either increased platelet activation or a high number of large, hyperaggregable platelets [76]. Activated platelets react to activated leukocytes and endothelial cells through adhesion molecules connecting inflammation and thrombosis [77]. Hekimsoy et al demonstrated that there is no link between MPV and HbA1c (glycated haemoglobin), fasting blood glucose, patient age, or duration of diabetes, suggesting that an increase in MPV values may be due to the diabetic status alone [76].…”

Section: Fructosamine and Blood Countmentioning

confidence: 99%

Investigation of Antihyperalgesic Effects of Different Doses of Sildenafil and Metformin in Alloxan-Induced Diabetic Neuropathy in Mice

PUȘCAȘU

2023

FARMACIA

View full text Add to dashboard Cite

Neuropathy is one of the most frequent and continuously growing complications of diabetes. Due to the multitude of mechanisms involved in the pathogenesis of diabetic neuropathy and the fact that current therapeutic strategies have limited success in relieving pain, the aim of our study was to investigate the antihyperalgesic action of two possible effective therapeutic agents: sildenafil (a phosphodiesterase 5 inhibitor) and metformin (an antihyperglycemic). Three consecutive doses of 150 mg/kg bw of alloxan were used to induce diabetic neuropathy. Metformin showed an antihyperalgesic effect for all 3 tested doses (150 mg/kg bw, 250 mg/kg bw and 500 mg/kg bw), while for sildenafil, only doses of 2.5 mg/kg bw and 3 mg/kg bw demonstrated a significant increase in pain reaction latency after 14 days of treatment in the hot-plate test. On the other hand, metformin 150 mg/kg bw, metformin 500 mg/kg bw, sildenafil 1.5 mg/kg bw and sildenafil 3 mg/kg bw showed the best antihyperlagesic effect in the tail withdrawal test after 14 days of treatment. Blood count highlighted increased WBC (white blood cells) values and decreased RBC (red blood cells), Hb (haemoglobin), and Hct (haematocrit) values in all diabetic groups, except the metformin 250 mg/kg bw and metformin 500 mg/kg bw groups, which showed the best glycaemic control according to blood fructosamine values. These findings indicate that alterations in blood count parameters may be prevented by good glycemic control. MPV (mean platelet volume) values were statistically increased for all diabetic groups when compared to the non-diabetic control group. Further studies are needed to investigate the mechanisms of action involved in antihyperalgesic activity. RezumatNeuropatia este una dintre cele mai frecvente și în continuă creștere complicații ale diabetului. Datorită multitudinii de mecanisme implicate în patogeneza neuropatiei diabetice și a faptului că strategiile terapeutice actuale au un succes limitat în ameliorarea durerii, scopul cercetării noastre a fost investigarea acțiunii antihiperalgice a doi agenți terapeutici, sildenafil (inhibitor de fosfodiesterază V) și metformin (antihiperglicemiant). Inducerea diabetului s-a realizat prin administrarea a 3 doze consecutive de 150 mg/kg corp aloxan. Metformin a prezentat efect antihiperalgic pentru toate cele 3 doze testate (150 mg/kg corp, 250 mg/kg corp și 500 mg/kg corp), în timp ce pentru sildenafil, doar dozele de 2,5 mg/kg corp și 3 mg/kg corp au prezentat o creștere seminificativă statistic a latenței reacției la durere după 14 zile de tratament în testul hot-plate. Pe de altă parte, metformin în dozele de 150 mg/kg corp și 500 mg/kg corp, și sildenafil 1,5 mg/kg corp și 3 mg/kg corp au dovedit cel mai bun efect antihiperalgic în testul de retracție a cozii a după 14 zile de tratament. Hemoleucograma a evidențiat creșterea valorilor leucocitelor și scăderea valorilor eritrocitelor, hemoglobinei și hematocritului în toate loturile diabetice, cu excepția loturilor tratate cu 250 mg/kg corp metformin și 500 mg...

show abstract

Primary platelet activation in recent-onset type 1 diabetes mellitus

Cited by 17 publications

References 15 publications

Deranged Platelet Calcium Homeostasis in Poorly Controlled IDDM Patients

Deranged Platelet Calcium Homeostasis in Poorly Controlled IDDM Patients

Review: The management of stable angina in diabetes

Investigation of Antihyperalgesic Effects of Different Doses of Sildenafil and Metformin in Alloxan-Induced Diabetic Neuropathy in Mice

Contact Info

Product

Resources

About